CC
CHRS icon

Clearline Capital’s Coherus Oncology CHRS Stock Holding History

Clearline Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-784,449
Closed -$816K – 103
2024
Q3 		$816K Hold
784,449
– – 0.03% 123
2024
Q2 		$1.36M Hold
784,449
– – 0.04% 108
2024
Q1 		$1.87M Buy
+784,449
New +$1.93M 0.09% 89
2019
Q2 		– Sell
-24,723
Closed -$337K – 52
2019
Q1 		$337K Buy
24,723
+12,261
+98% +$164K 0.18% 37
2018
Q4 		$113K Buy
+12,462
New +$144K 0.08% 57

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Clearline Capital's CHRS Position: Q4 2024 in Review

Clearline Capital sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 784,449 shares — an estimated $816K sold.

Clearline Capital first reported a position in CHRS in Q4 2018 and held it in 5 quarters. The position peaked at $1.87M in Q1 2024. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Clearline Capital reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Clearline Capital sold 784,449 Coherus Oncology shares in Q4 2024, an estimated $816K.
  • Clearline Capital first reported a position in Coherus Oncology in Q4 2018 and held it in 5 quarters.
  • Clearline Capital's Coherus Oncology position peaked at $1.87M in Q1 2024.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Clearline Capital's 13F filing for Q4 2024, filed 14 Feb 2025.